Clincosm LogoSign in Get a demo

ARBODOCC: Human Epidemiology of Newly Identified Arboviruses

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Recruiting
CT.gov ID
NCT04954352
Collaborator
UMR ASTRE (CIRAD) (Other), Institut Pasteur (Industry), UMR PCCEI (Other)
400
Enrollment
1
Location
60
Anticipated Duration (Months)
6.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A local network is being set up to study the impact of arboviruses in our region. It is committed to a one-health approach, in particular with research without a priori for new viruses hosted among vectors and wildlife. The candidates identified by high throughput sequencing approaches will serve as a basis for the development of serological and molecular tools for their detections. These tools will be used to assess the possible circulation of these new viruses in humans in biological collections created within the framework of this project Arbodocc

.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    400 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Epidemiology in Humans of New Arbovirusus Sorted Out From Metagenomic Screen in Local Vectors and Animal Hosts.
    Actual Study Start Date :
    Jan 1, 2020
    Anticipated Primary Completion Date :
    Dec 20, 2024
    Anticipated Study Completion Date :
    Dec 30, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Seroprevalence [1 day]

      Detection of antibodies targeting specific antigens of newly identified arboviruses

    Secondary Outcome Measures

    1. Molecular detection [1 day]

      Detection of newly identified arboviruses genome

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion criteria:
    • Patients admitted at the Monpellier University Hospital for any infectious syndrome compatible with an arboviral infection with samples available
    Exclusion criteria:
    • Informed consent non obtain for samples used

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uh Montpellier Montpellier France 34295

    Sponsors and Collaborators

    • University Hospital, Montpellier
    • UMR ASTRE (CIRAD)
    • Institut Pasteur
    • UMR PCCEI

    Investigators

    • Study Director: Vincent Foulongne, PhD, UH MONTPELLIER

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Montpellier
    ClinicalTrials.gov Identifier:
    NCT04954352
    Other Study ID Numbers:
    • RECHMPL21_0297
    First Posted:
    Jul 8, 2021
    Last Update Posted:
    Jul 8, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Montpellier
    Patients with arboviral infection compatible signs
    Unexplained isolated fever
    Neurological infection conditions without any identified etiology
    Arbovirus
    Arboviral like infectious disease
    Additional relevant MeSH terms:
    Infections
    Communicable Diseases
    Severe Acute Respiratory Syndrome
    Arbovirus Infections

    Study Results

    No Results Posted as of Jul 8, 2021